AMGN catalyst calendar

AMGEN INC

Upcoming catalysts
35
Cash runway
Cash generating
Cash & investments
$13989M
Phase 3 programs
46

AMGEN INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is Next quarterly earnings (projected) on November 3, 2026, a projected date rather than a confirmed one. There are 35 upcoming events on record.

AMGEN INC generates cash from operations, so a burn-based runway figure does not apply.

Across 358 concluded trials, 86% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 3, 2026 est. Next quarterly earnings (projected) Earnings —
December 14, 2026 Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) Trial Milestone Phase 3
December 31, 2026 Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) Trial Milestone Phase 1
January 21, 2027 Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight Trial Milestone Phase 3
January 21, 2027 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight Trial Milestone Phase 3
March 23, 2027 Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose Trial Milestone Phase 1
April 10, 2027 A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma Trial Milestone Phase 1
April 19, 2027 Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) Trial Milestone Phase 3
April 27, 2027 A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China Trial Milestone Phase 4
May 4, 2027 Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta Trial Milestone Phase 3
June 30, 2027 A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis Trial Milestone Phase 3
June 30, 2027 A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) Trial Milestone Phase 3
July 31, 2027 A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration Trial Milestone Phase 3
August 30, 2027 Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy Trial Milestone Phase 3
October 2, 2027 A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus Trial Milestone Phase 1
November 24, 2027 A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL Trial Milestone Phase 1/Phase 2
December 26, 2027 Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) Trial Milestone Phase 3
December 30, 2027 A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) Trial Milestone Phase 2
January 29, 2028 An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease Trial Milestone Phase 2
March 7, 2028 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone Trial Milestone Phase 4
March 18, 2028 A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) Trial Milestone Phase 1
April 19, 2028 Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta Trial Milestone Phase 3
June 18, 2028 A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout Trial Milestone Phase 3
September 4, 2028 Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes Trial Milestone Phase 3
January 2, 2029 Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) Trial Milestone Phase 3
January 4, 2029 A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) Trial Milestone Phase 3
April 30, 2029 A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Trial Milestone Phase 4
August 10, 2029 A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC Trial Milestone Phase 2
December 11, 2029 A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) Trial Milestone Phase 3
January 1, 2030 AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors Trial Milestone Phase 1
February 7, 2030 Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease Trial Milestone Phase 3
May 30, 2030 First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Trial Milestone Phase 1
June 23, 2031 Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) Trial Milestone Phase 1
September 27, 2031 A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy Trial Milestone Phase 3
March 17, 2036 A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis Trial Milestone Phase 3

Track AMGN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open AMGN in the tracker

Recent history

DateEventTypePhase
September 16, 2026 Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity Trial Milestone Phase 1
August 27, 2026 Effect of Maridebart Cafraglutide on the Heart's Electrical Activity Trial Milestone Phase 1
August 4, 2026 Quarterly results filed (8-K) Earnings —
July 23, 2026 A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity Trial Milestone Phase 3
July 2, 2026 A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations Trial Milestone Phase 1
May 19, 2026 8-K filed: Leadership change Corporate —
May 14, 2026 A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Trial Milestone Phase 2
April 30, 2026 Quarterly results filed (8-K) Earnings —
April 28, 2026 A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome Trial Milestone Phase 2
April 22, 2026 8-K filed: Leadership change Corporate —
April 17, 2026 A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Trial Milestone Phase 3
February 26, 2026 A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function Trial Milestone Phase 1
February 19, 2026 8-K filed: Material agreement Corporate —
February 3, 2026 Quarterly results filed (8-K) Earnings —
December 19, 2025 TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study Trial Milestone Phase 4
December 2, 2025 Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants Trial Milestone Phase 1
November 22, 2025 A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants Trial Milestone Phase 1
November 21, 2025 A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body Trial Milestone Phase 1
November 20, 2025 A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis Trial Milestone Phase 3
November 4, 2025 Quarterly results filed (8-K) Earnings —
August 5, 2025 Quarterly results filed (8-K) Earnings —
July 31, 2025 A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Trial Milestone Phase 3
May 28, 2025 A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment Trial Milestone Phase 2
May 22, 2025 A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity Trial Milestone Phase 1
May 1, 2025 Quarterly results filed (8-K) Earnings —
April 11, 2025 A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis Trial Milestone Phase 3
February 24, 2025 A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis Trial Milestone Phase 2
January 29, 2025 Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer Trial Milestone Phase 3
November 29, 2024 A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants Trial Milestone Phase 1
November 28, 2024 A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) Trial Milestone Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.